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Abstract
Objective: To measure the prices and availability of selected medicines in Shaanxi Province after the implementation of new
healthcare reform in 2009.
Methods: Data on the prices and availability of 47 medicines were collected from 50 public and 36 private sector medicine
outlets in six regions of Shaanxi Province, Western China using a standardized methodology developed by the World Health
Organization and Health Action International from September to October 2010. Medicine prices were compared with
international reference prices to obtain a median price ratio. Affordability was measured as the number of days’ wages
required for the lowest-paid unskilled government worker to purchase standard treatments for common conditions.
Findings: The mean availabilities of originator brands and lowest-priced generics were 8.9% and 26.5% in the public sector,
and 18.1% and 43.6% in the private sector, respectively. The public sector procured generics and originator brands at
median price ratios of 0.75 and 8.49, respectively, while patients paid 0.97 and 10.16. Final patient prices for lowest-priced
generics and originator brands in the private sector were about 1.53 and 8.36 times their international retail prices,
respectively. Public sector vendors applied high markups of 30.4% to generics, and 19.6% to originator brands. In the
private sector, originator brands cost 390.7% more, on average, than their generic equivalents. Generic medicines were
priced 17.3% higher in the private sector than the public sector. The lowest-paid government worker would need 0.1 day’s
wages to purchase captopril for lowest-priced generics from private sector, while 6.6 days’ wages for losartan. For originator
brands, the costs rise to 1.2 days’ wages for salbutamol inhaler and 15.6 days’ wages for omeprazole.
Conclusions: The prices, availability and affordability of medicines in China should be improved to ensure equitable access
to basic medical treatments, especially for the poor. This requires multi-faceted interventions, as well as the review and
refocusing of policies, regulations and educational interventions.
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Introduction
Access to essential medicines is integral to fulfilling the rights of
citizens to the highest standards of health. However, at least one
third of the world’s population has no regular access to medicines
[1]. Numerous reasons exist for the lack of access to essential
medicines, but in many cases high drug prices are a major barrier.
In China, total expenditure on health care in 2010 was 4.92% of
gross domestic product (GDP), just under the 5% level recom-
mended by the World Health Organization (WHO). In 2010
Chinese national healthcare expenditures were USD 289.6 billion,
with out-of-pocket health expenditure of nearly USD 102.8 billion.
Pharmaceuticals account for about half of total health spending in
China, representing 43.4 percent of spending per inpatient episode
and 52.2 percent of spending per outpatient visit [2]. This
proportion is one of the highest in the world, and compares to an
average of around 17% in the OECD countries [3]. The high cost
of medical care services and medicines is considered the major
obstacle in accessing health care in China [4].
The new round of healthcare reform launched in 2009 included
a number of measures to tackle high medical costs, such as
increasing government spending to provide for all of those in need,
establishing a national essential medicines system to reduce
medicines prices, and promoting free medical treatments and
advocating prevention. According to this healthcare reform plan,
by 2012, all primary health care institutions (namely urban
community health care centers, rural township hospitals, and
village clinics) receiving government subsidies will be required to
stock and dispense essential medicines at zero mark-up [5].
Shaanxi Province, with a population of nearly 37.62 million
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the capital. The Shaanxi Government initially piloted the essential
medicine policy with zero mark-up in all primary health care
institutions of two cities (Yulin and Baoji) in June 2009, and then
implemented it in other cities after November 2010. Primary
health care institutions thus can only stock and dispense
medications currently included in the National Essential Medicine
List (NEML) or Provincial Essential Medicine List (PEML). All
medicines stocked by primary health care institutions are procured
from the Department of Drug Price Bidding at the Shaanxi
Provincial Department of Health under a system of ‘‘unified
bidding, unified pricing, and unified distribution’’, and sold with
zero mark-up [6]. Meanwhile, the National Development and
Reform Commission (NDRC) regularly lowers medicine prices to
ease the burden of patients. In theory, these changes should reduce
inefficiencies in drug delivery [7]. However, governments have
little information on supply, pricing, distribution, and the use of
drugs to help them construct sound medicine pricing policies or
evaluate their impact [8].
In May 2003, the World Health Organization (WHO)
collaborated with Health Action International (HAI) to develop
a standardized method for surveying medicine prices, availability,
affordability, and price components in low- and middle-income
countries [9]. Three surveys have been carried out using the
WHO/HAI methodology, in Shandong [10], Shanghai [11] and
Hubei [12], and all revealed an alarming lack of access to
affordable essential medicines in both the public and private
sectors in China. These three surveys were conducted in eastern
and central China from 2004 to 2008, prior to China’s new
healthcare reform, and research on the availability and use of
essential medicines in China’s underdeveloped western regions is
scarce. The main goal of this study was to clarify medicine pricing
in China by conducting a cross sectional survey to measure the
prices, availability and affordability of a standardized set of
medicines in Shaanxi Province, Western China from September to
October 2010, utilizing the WHO/HAI methodology. To our
knowledge, this is the first study of its type in China since the
implementation of the essential medicine system in 2009. Previous
work on this area has been limited to descriptive studies [13–15]
and one survey [16] that analyzed the essential medicines list,
policy trends and prescribing behaviors.
Methods
Ethics Statement
Xi’an Jiaotong University Health Science Center, Shaanxi
Provincial Department of Health and Shaanxi Food and Drug
Administration approved the study prior to data collection.
Sampling
A systematic sampling method was used to select medicine
outlets. The major urban centre of Xi’an was selected as one
survey area, and an additional five areas reachable within one
day’s drive from Xi’an were randomly chosen. The final sample
comprised the following six survey areas: Xi’an, Yulin, Xi’anyang,
Baoji, Shangluo and Weinan. In each survey area, the sample of
public sector medicine outlets was identified by first selecting the
main public hospital. An additional four public medicine outlets
per survey area were then randomly selected from those within
four hour’s drive from the main hospital. The public sector sample
therefore contained five public medicine outlets in each of the six
survey areas, for a total of 30 public outlets. The private sector
sample was identified by selecting the private sector medicine
outlet closest to each of the selected public medicine outlets,
yielding a total of 30 private outlets. Back-up facilities were
selected in case the availability of the survey medicines was less
than 50% at a given outlet. The sample of public and private
medicine outlets is listed in Table S1.
Selection of Medicines to be Surveyed
Among 47 medicines included in the survey, 27 belonged to the
core list medicines suggested by WHO/HAI for international
comparison, and 20 were supplementary drugs. The core list
medicines were selected on the basis of the global disease burden.
The supplementary medicines were selected based on local
importance, the NEML and disease burden, and finalized after
expert opinion and feedback from international experts (from HAI
and WHO) and an advisory committee (including practicing
pharmacists, academics, and experts from the Drug Administra-
tion Authority of Shaanxi Province). Table S2 lists all the survey
medicines. Of the 47 medicines surveyed, 33 were on the NEML.
Since our survey started prior to the issue of the PEML in October
2010, three medicines listed on the PEML subsequently were no
longer considered essential medicines. For each medicine,
information was collected on the availability and price of both
the originator brand (OB), and the lowest-priced generic (LPG)
equivalent found at each medicine outlet. The LPG was
determined at the facility level.
Data Collection and Entry
Twelve trained data collectors organized in pairs to visit
medicine outlets and recorded medicine availability and price
using a standardized form. Three prices were recorded, namely
the procurement price and patient price in public medicine outlets,
and the patient price in private pharmacies. Procurement data
were generally obtained from the Shaanxi government procure-
ment office [17], where procurement data were unavailable,
procurement prices were collected at individual medicine outlets.
Survey data were entered into the pre-programmed Excel
Workbook (WHO/HAI 2008) by two people using a double
entry technique. For a more detailed description of the survey
method, see the Methods section of the manual published by
WHO/HAI [18].
Statistical Analysis
The availability of individual medicines is calculated as the
percentage (%) of medicine outlets where the medicine was found.
Mean availability is also reported for the overall ‘‘basket’’ of
medicines surveyed. The availability data only refer to the day of
data collection at each particular facility and may not reflect
average monthly or yearly availability of medicines at individual
facilities.
As an external benchmark, and to facilitate cross-country
comparisons, medicine prices obtained during the survey are
expressed as median price ratios (MPRs), or the ratio of a
medicine’s median unit price across outlets to the median unit
price in the Management Sciences for Health 2009 Price Indicator
Guide [19], i.e. the international reference price (IRP). MSH
international reference prices were selected as the most useful
standard since they are updated frequently, always available and
relatively stable. These prices are recent procurement prices
offered by both not-for-profit and for-profit suppliers to developing
countries for multi-source products. When no supplier prices are
available, buyer prices are used. The MPRs will not be calculated
until at least four procurement prices, or at least four public or
private sector patient prices, are entered for the medicine in
question. Generally, an MPR of 1 or less indicates an efficient
public sector procurement system. Unlike procurement prices,
Evaluating Drug Prices and Availability
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patient prices are high, low or about right. For the purposes of this
discussion we use the following cut-off points of MPRs for patient
prices to represent acceptable local price ratios: Patient prices in
the public sector: MPR#1.5; Patient prices in private pharmacies:
MPR#2.5 [20]. A Kruskal-Wallis test was applied, and p,0.05
was used to indicate significant difference.
According to the standard WHO/HAI methodology [18], the
affordability of treating 22 common conditions was assessed by
comparing the total cost of medicines prescribed at a standard
dose with the daily wage of the lowest paid unskilled government
worker, which was RMB 25.3333/day (USD 3.7152) at the time of
the survey based on figures from the Department of Human
Resources and Social Security of Shaanxi Province [21].
Results
Of the outlets sampled, public procurement prices were
available for 15 OBs and 28 generics out of the 47 medicines
surveyed, public patient prices were collected from 50 public
medicine outlets, and private patient prices were collected from 36
private pharmacies.
Medicine Availability
The mean availability of OBs and LPGs was 8.9% and 26.5%,
respectively, in the public sector, and 18.1% and 43.6% in the
private sector. Analysis of survey medicines listed on the NEML
[22] also found low availability. Separate availability analysis for
33 medicines listed on the NEML showed that mean availability in
the public sector was 5.8% for OBs and 30.2% for LPGs, while
mean availability in private sector retail pharmacies was 9.9% for
OBs and 48.1% for LPGs.
Table 1 lists the availability of individual medicines in both the
public and private sectors. Only 16 OBs were found in the public
sector and 23 in the private sector. Only 10 LPGs in the public
sector and 19 in the private sector had .50% availability.
In all six regions, the mean availability of sampled medicines
was higher in the private sector than the public sector, while
generic medicines were more available than originator brands in
both sectors. Analysis of medicine availability in primary health
care institutions showed that mean availability of generic
medicines ranged from 14.4% in Shangluo to 27.1% in Baoji.
For originator brands, Yulin and Xi’an had the highest public
sector availability of 7.1%, while Shangluo had the lowest public
sector availability of 1.1%.
Medicine Prices
Overall the public sector procures 28 generics at 0.75 times
their IRPs, and 15 OBs at 8.49 times their IRPs. The MPRs of
seven OBs – amlodipine (25.61), ceftriaxone injection (17.41),
fluoxetine (108.39), gliclazide (11.43), loratadine (27.25), metfor-
min (18.17), and omeprazole (56.59) – were more than ten times
their IRPs. Fifteen LPGs were procured at lower prices than the
IRPs; however, four medicines were more than five times the
reference price, including amlodipine (5.16), diclofenac (21.87),
enalapril (7.83) and loratadine (5.68).
Table 2 compares the price of medicines procured and then sold
to patients in the public sector. Results show that final patient
prices are 19.6% and 30.4% higher than procurement prices for
15 OBs and 28 generic equivalents, respectively. There were
significant variations in mark-up rates (range: 14.7–48.1%; see
Table S3) for 15 OBs, with 48.1% for simvastatin being the
highest. Meanwhile, there were large differences in mark-up rates
(range: 3.3–80.0%) among the 28 generic medicines.
To reveal the relations between drug prices in the public sector
and procurement prices, we analyzed the mark-up rates. For
generic medicines procured at below IRP, the median mark-up
was 27.2%, as shown in Table S3 (the highest mark-up was 80.0%
for aminophylline). For generic medicines procured above IRP
(such as diclofenac, enalapril and loratadine), the median mark-up
was 15.1%. However, the actual add-on costs of medicines
procured below IRP were less than those for generic medicines
procured at higher prices than the IRPs (median add-on cost: 0.11
vs. 0.66). Therefore, high procurement prices are a major
contributor to high retail prices (the higher the procurement
price, the more profit a hospital can make through its mark-up).
In the private sector retail pharmacies, the median MPR for 15
OBs was 8.36 times the IRP, while the median MPR for 37 LPGs
was 1.53 times the IRP (Table 2). Further analysis of 11 medicines
for which both OBs and generically equivalent products were
found showed that in the private sector, OBs cost 390.7% more,
on average, than their generic equivalents. Thus, patients pay
substantially more for originator brand medicines when lower-cost
generics are unavailable.
In Table 3, only those medicines found in both public and
private sector medicine outlets were included in the analysis to
enable price comparison between the two sectors. Results showed
that final patient price in the private sector is 16.5% lower than in
the public sector for OBs, and 17.3% higher for generic
equivalents.
High variation across the six survey regions was noted for
originator brands in the public sector. The highest median MPR,
19.63, was found in Xi’an whilst the lowest, 6.19, was in Baoji.
Prices for lowest priced generics showed less variation across the
regions with the lowest median MPR occurring in Yulin (0.6) and
the highest in Xi’anyang (1.02) (Figure 1). The median MPRs for
originator brands and generics in the private sector did not differ
significantly across the six regions surveyed, and ranged from 6.76
in Weinan to 9.65 in Yulin for originator brands, and from 0.65 in
Weinan to 0.92 in Baoji, respectively (Figure 2). However, because
of the small sample size in each region (5 medicine outlets per
sector, with each medicine available in at least 4), the results
should be interpreted with caution.
Of all 94 medicines studied (47 OBs and 47 LPGs), eight were
found in all six regions. A Kruskal-Wallis test revealed no
significant difference in MPRs of these eight medicines across
the six regions, with X
2 (5, n=48)=0.888, p=0.971.
Affordability
The affordability of treatments for 11 different health conditions
is listed in Table 4. In general, OB products were less affordable
than the LPG equivalents in both the public and private sectors.
The affordability of LPGs in the public sector was reasonable (with
standard treatment costing a day’s wage or less) for most
conditions, except for amlodipine (1.7 days’ wages), nifedipine
retard (1.5 days’ wages), simvastatin (2.2 days’ wages) and
diclofenac (2.3 days’ wages).
In the private sector, LPGs had reasonable affordability for
most conditions, while the following seven LPGs cost over a day’s
wage: simvastatin, amlodipine, fluoxetine, lisinopril, losartan,
nifedipine retard and diclofenac. The most affordable standard
treatments were generally those for treating acute conditions like
adult respiratory infection (0.1–0.4 days’ wages). When OBs are
prescribed and dispensed in the private sector, some treatment
costs are surprisingly high. For example, treating peptic ulcer with
omeprazole required 15.6 days’ wages, while treating depression
with fluoxetine cost 11.5 days’ wages.
Evaluating Drug Prices and Availability
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Figure 3 displayed the availability and price of LPGs in the
public sector. The availability score for each drug is depicted on
the x-axis, while the y-axis shows the value of MPR. The figure
can be divided into roughly four quadrants. The lower right
quadrant (quadrant IV) contains drugs with low MPR and high
Table 1. Availability of medicines in the public sectors and the private retail pharmacy sectors.
Availability Public sector Private sector
Originator brand Lowest price generic Originator brand Lowest price generic
Medicines not
found in any
outlets
Aciclovir, aminophyline,
amitriptyline, amoxicillin,
atenolol, captopril,
carbamazepine, cefradine,
cephalexin, cimetidine
ciprofloxacin, co-trimoxazole,
diazepam, diclofenac, digoxin
enalapril, erythromycin,
fluconazole, glibenclamide,
hydrochlorothiazide, ibuprofen,
lisinopril, lovastatin,
metronidazole, nifedipine
retard, ofloxacin, paracetamol,
phenytoin, ranitidine,
rifampicin, sodium valproate
Aciclovir, atenolol,
beclometasone inhaler,
ciprofloxacin, glibenclamide,
ibuprofen, ketoconazole,
ofloxacin
Aciclovir, aminophylline,
amitriptyline, atenolol,
captopril, carbamazepine,
cefradine, cephalexin,
cimetidine, ciprofloxacin,
co-trimoxazole, diazepam,
diclofenac,enalapril,
erythromycin, glibenclamide,
hydrochlorothiazide, ibuprofen,
lovastatin, metronidazole,
ofloxacin, paracetamol,
phenytoin, ranitidine,
rifampicin
Atenolol, beclometasone inhaler,
diazepam, ketoconazole
Medicines found
in less than 25%
of outlets
Azithromycin, beclometasone
inhaler, ceftriaxone injection,
fluoxetine, loratadine, losartan,
metformin, omeprazole,
simvastatin
Albendazole, amitriptyline,
amlodipine, amoxicillin,
atorvastatin, cefradine,
cephalexin, diazepam,
diclofenac, erythromycin,
fluconazole, fluoxetine,lisinopril,
loratadine, lovastatin,metformin,
miconazole nitrate, paracetamol,
salbutamol inhaler, simvastatin
Amoxicillin, azithromycin,
beclometasone inhaler,
ceftriaxone injection,
digoxin, fluconazole
fluoxetine, lisinopril,
nifedipine retard, sodium
valproate
Albendazole, amitriptyline,
torvastatin, cefradine,
ciprofloxacin, erythromycin,
fluconazole, fluoxetine,
glibenclamide, ibuprofen,
lisinopril, losartan, miconazole
nitrate, ofloxacin, paracetamol,
Medicines found
in 25 to 50% of
outlets
Albendazole, amlodipine,
atorvastatin, gliclazide,
ketoconazole, salbutamol
inhaler
Carbamazepine, cimetidine,
gliclazide, nifedipine retard,
phenytoin, ranitidine,
rifampicin, sodium
valproate
Losartan, metformin,
omeprazole, salbutamol
inhaler, simvastatin
Aciclovir, amlodipine, cephalexin,
diclofenac, loratadine, lovastatin
metformin, phenytoin,
simvastatin
Medicines found
in 50 to 75% of
outlets
NONE Azithromycin, co-trimoxazole,
digoxin,enalapril,
hydrochlorothiazide
Amlodipine, atorvastatin,
gliclazide, ketoconazole
Aminophylline, carbamazepine,
ceftriaxone injection, digoxin,
gliclazide, nifedipine retard,
salbutamol inhaler, sodium
valproate
Medicines found
in over 75% of
outlets
Miconazole nitrate Aminophylline, captopril,
ceftriaxone injection,
metronidazole, omeprazole
Albendazole, loratadine,
miconazole nitrate
Amoxicillin, azithromycin,
captopril, cimetidine, co-
trimoxazole, enalapril,
hydrochlorothiazide,
metronidazole, omeprazole,
ranitidine, rifampicin
doi:10.1371/journal.pone.0070836.t001
Table 2. Median MPRs for OBs and LPGs in the public and private sectors.
Public sector Private sector
Product type
No. of
medicines
Median MPRs
Procurement price
Median MPRs
Retail price
% difference patient
prices to procurement
No. of
medicines
Median MPRs
Retail price
Lowest price generic
All 28 0.75 0.97 30.4% 37 1.53
Core list 18 1.59 1.84 20 1.46
Supplementary list 10 0.54 0.76 11 1.08
NEML 21 0.55 0.76 26 0.86
Originator brand 15 8.49 10.16 19.6% 15 8.36
OBs: Originator brands; LPGs: Lowest-priced generics; NEML: National Essential Medicine List (2009).
doi:10.1371/journal.pone.0070836.t002
Evaluating Drug Prices and Availability
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e70836availability, for example metronidazole which has 98.0% avail-
ability and a MPR of 0.83. The upper left quadrant (quadrant I)
contains drugs with high MPR and low availability. In the case of
these medicines, patients face both high costs and high difficulty in
obtaining them. For example, diclofenac was available in only
20.0% of surveyed public sector hospitals and cost over 25 times
the IRP. As shown in Figure 4, a slightly more optimistic situation
exists in the private sector where 16 medicines are in quadrant IV,
with good access and low cost, and ten medicines are in quadrant
I, with low availability and high price. Two medicines for
depression (amitriptyline and fluoxetine) are in quadrant I in both
figures (fluoxetine was absent in Figure 3 owing to the lack of
associated MPR data), making depression treatment potentially
challenging in China.
Notably, some generics are easily accessed at low cost in both
the public and private sectors, such as aminophylline, azithromy-
cin, captopril, ceftriaxone injection, cimetidine, co-trimoxazole,
digoxin, hydrochlorothiazide, metronidazole and ranitidine.
Discussion
To date, four surveys [10–12,23] have been carried out in
China using the standardized, reliable methodology developed by
WHO/HAI [18]. As the first study to apply the 2008 edition of the
methodology to the less developed western region of China, the
results of this medicine survey, together with three previously
conducted surveys in eastern and central China, provide clearer
insights into prices, availability, and affordability of medicines in
China.
In 2009, the Chinese government launched a new round of
healthcare reform, the main drug-related component of which is
the implementation of a National Essential Medicines List.
Monitoring of implementation and evaluation of the impact of
essential drug policy in China is urgently needed. This study will
fill in data gaps in the assessment of the prices, availability and
affordability of essential medicines in China’s western regions.
Results indicate that overall the government procurement
agency is purchasing originator brands efficiently, but pays very
high prices. These medicines are then on-sold to patients at over
19.6% more than the purchase prices as a result of add-on costs in
the public sector distribution chain. Similar results were found in
the Shandong [10], Shanghai [11] and Hubei [12] studies, and the
MPRs of procurement prices were 0.62, 1.53 and 0.74 times the
international reference prices for LPGs, while for OBs they were
6.30, 6.7 and 9.78, respectively. In Malaysia, the public
procurement prices of medicines were moderately high relative
to international prices, where the median MPRs of 2.44 and 1.09
were recorded for OBs and LPGs, respectively [24]. In contrast,
seven Indian states [25–32] showed more efficient procurement
and pricing in the public sector, where the lowest median MPR of
LPGs was found in Haryana (0.33), and the highest in Rajasthan
(0.96).
Lower availability of OBs than generic alternatives was seen in
both the public and the private sectors, which could be attributed
to their substantially higher prices. Medicines listed on the NEML
had worse availability than other medicines in both sectors,
especially in the public sector. Because of low availability of
essential medicines in public hospitals, some patients had to
purchase their medicines from retail pharmacies after consultation
Table 3. Median MPRs for medicines found in both the public and private sectors.
Product type
Median MPR Public sector
patient prices
Median MPR Private sector
patient prices % difference private to public
Obs (n=14 medicines) 9.98 8.83 216.5%
LPGs (n=27 medicines) 0.83 0.98 17.3%
OBs: Originator brands; LPGs: Lowest-priced generics.
doi:10.1371/journal.pone.0070836.t003
Figure 1. Regional Variations in Median MPRs in the Public
Sectors. High and less variation in the median MPRs for OBs and LPGs,
respectively, were observed in the public sectors across the six survey
regions.
doi:10.1371/journal.pone.0070836.g001
Figure 2. Regional Variations in Median MPRs in the Private
Retail Sector Pharmacies. Less variations in the median MPRs for
OBs and LPGs were observed in the private sectors across the six survey
regions.
doi:10.1371/journal.pone.0070836.g002
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were found in any of the retail pharmacies surveyed (not even at
other strengths). Unavailability of diazepam at retail pharmacies is
probably because of its status in China as a strictly controlled
psychotropic drug, which means that many pharmacies do not
stock it. Atenolol was not found in any of the retail pharmacies,
probably due to it not being used as a first line antihypertensive
drug in China.
At the time of the survey, the zero mark-up policy had been
conducted in all primary health care institutions in Yulin and
Baoji. Although still very low, in the grass-roots hospitals surveyed,
the highest mean availability of LPGs was in Baoji while that of
OBs was in Yulin, and the prices were relatively low. The
preliminary results showed that medicine availability was higher in
two regions that had implemented a zero mark-up policy on drug
sales than in regions without implementing such a policy. Further
impacts of policy changes should be measured by establishing a
monitoring system to regularly monitor medicine prices and
availability [33]. To more fully study the medicine situation, the
list of survey medicines should include more from both the NEML
(2009) and the PEML (2010).
Although it is difficult to assess true affordability, treatments
costing one day’s wage or less (for a full course of treatment for an
acute condition, or a 30-day supply of medicine for chronic
diseases) are generally considered affordable. Notably, treatment
costs refer to medicines only and exclude the additional costs of
consultation and diagnostic tests. Further, since many people in
China earn less than the lowest government wage, even treatments
that appear affordable are too costly for the poorest segments of
the population. Given that 16.6% of the population are living
below the international poverty line, defined as income of less than
$1/day, even treatments which appear affordable are out-of-reach
for a substantial number of people. Meanwhile, even where
individual treatments appear affordable, individuals or families
who need multiple medications may quickly face unmanageable
drug costs. An example is provided below of a family where the
father has an ulcer and the child has asthma, treated with
omeprazole and salbutamol inhaler, respectively. If the family
income is equivalent to the lowest-paid government worker’s
salary, medicine costs assuming purchase of LPGs are 0.8 days’
wages if purchasing via the public sector and 1.0 days’ wages for
the private sector. If OBs are purchased, treatment costs are 18.2
days’ wages for the public sector and 16.8 for the private sector.
Limitations of this Study
The present study has three limitations that need to be
acknowledged and addressed. The first limitation concerns the
availability of medicines. Availability data were collected at a
specific point in time and involved a specific product dosage form
and strength; as a result, the data may not reflect average
Table 4. Number of days’ wages of the lowest paid government worker needed to purchase standard treatments.
Day’s wages to pay for treatment
public sector private sector
Condition Drug name Strength
No. of
units a day
Duration
days OBs LPGs OBs LPGs
Asthma salbutamol 0.1 mg/dose 200 as needed 1.3 0.2 1.2 0.2
beclometas 0.05 mg/dose 200 as needed 1.9 – 1.8 –
Diabetes metformin 500 mg 3 30 5.7 – 4.9 0.3
gliclazide 80 mg 1 30 1.6 0.6 1.3 0.5
Hypertension amlodipine 5 mg 1 30 7.0 1.7 6.3 1.3
captopril l 25 mg 2 30 – 0.1 – 0.1
lisinopril 10 mg 2 30 – – – 5.0
losartan 50 mg 1 30 8.6 7.5 6.6
nifedipine retard 20 mg 2 30 – 1.5 10.0 1.4
Hypercholesterolaemia simvastatin 20 mg 1 30 5.4 2.2 4.5 1.9
atorvastatin 20 mg 1 30 12.5 11.0 –
Depression amitriptyline 25 mg 3 30 – 0.6 0.7
fluoxetine 20 mg 1 30 12.3 11.5 2.9
Adult ciprofloxacin 500 mg 2 7 – – 0.1
respiratory amoxicillin 500 mg 3 7 – 0.7 – 0.4
Infection ceftriaxone 1 g/vial 1 as needed 3.7 0.1 – 0.1
Paediatric respiratory
Infecion
co-trimoxazole (80+400)
mg/ml
27– 0 . 0 – 0 . 0
Arthritis diclofenac 50 mg 2 30 – 2.3 – 2.1
Ulcer omeprazole 20 mg 1 30 16.9 0.6 15.6 0.8
ranitidine 150 mg 2 30 – 0.2 – 0.2
Epilepsy carbamazepine 100 mg 2 30 – 0.1 – 0.1
Viral infection aciclovir 200 mg 5 5 – – – 0.4
OBs: Originator brands; LPGs: Lowest-priced generics.
doi:10.1371/journal.pone.0070836.t004
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the specific list of survey medicines, and does not account for the
availability of alternate strengths or dosage forms, or therapeutic
alternatives.
The second limitation involves the reliability of median price
ratios, which may be skewed when international reference prices
are based on limited data. In cases where very few supplier prices
are available, or where there is no supplier price and the buyer
price is used as a proxy, MPR results can be skewed by a
particularly high or low international reference price [34].
The final limitation is that calculating affordability based on
government worker wages may lead to over-optimistic results since
a significant proportion of the population earns less than this.
Conclusions
In Shaanxi Province, low availability was observed for all
medicines surveyed, particularly for medicines listed on the NEML
in the public and private sectors. Considerable price differences
were seen between originator brands and generics in both sectors.
OBs were more expensive than LPGs in both the public and
private sectors. Medicines are often unaffordable for ordinary
citizens. The price, availability and affordability of medicines in
China should be improved to ensure equitable access to basic
medical treatments, especially for the poor.
Figure 3. Comprehensive analysis of medicine availability and retail price in the public sector (LPGs). The availability score for each
drug is depicted on the x-axis, while the y-axis shows the value of MPR.
doi:10.1371/journal.pone.0070836.g003
Figure 4. Comprehensive analysis of medicine availability and
retail price in the private sector (LPGs). The availability score for
each drug is depicted on the x-axis, while the y-axis shows the value of
MPR.
doi:10.1371/journal.pone.0070836.g004
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